Skip to main content

Analysts Are Bullish on Top Healthcare Stocks: Owlet (OWLT), Exelixis (EXEL)

Tipranks - Sun Dec 14, 2025

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Owlet (OWLTResearch Report) and Exelixis (EXELResearch Report) with bullish sentiments.

Claim 50% Off TipRanks Premium and Invest with Confidence

Owlet (OWLT)

In a report released today, Andrew Brackmann from William Blair maintained a Buy rating on Owlet. The company’s shares closed last Friday at $14.74.

According to TipRanks.com, Brackmann is a 5-star analyst with an average return of 32.3% and a 71.2% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Adaptive Biotechnologies, and Abbott Laboratories. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Owlet with a $14.50 average price target, a 0.8% upside from current levels. In a report issued on December 4, Northland Securities also maintained a Buy rating on the stock with a $15.50 price target.

See Insiders’ Hot Stocks on TipRanks >>

Exelixis (EXEL)

In a report issued on December 11, Akash Tewari from Jefferies maintained a Buy rating on Exelixis, with a price target of $46.00. The company’s shares closed last Friday at $40.88.

According to TipRanks.com, Tewari is a 5-star analyst with an average return of 13.2% and a 55.2% success rate. Tewari covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Enanta Pharmaceuticals, and Terns Pharmaceuticals. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Exelixis with a $44.09 average price target, a 5.8% upside from current levels. In a report issued on December 5, Morgan Stanley also maintained a Buy rating on the stock with a $45.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.